438 related articles for article (PubMed ID: 30068236)
21. Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview.
Davidson JA; Sloan L
Adv Ther; 2017 Jan; 34(1):41-59. PubMed ID: 27854055
[TBL] [Abstract][Full Text] [Related]
22. Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.
Kim ES; Deeks ED
Drugs; 2015 Sep; 75(13):1547-57. PubMed ID: 26323340
[TBL] [Abstract][Full Text] [Related]
23. Empagliflozin for the treatment of type 2 diabetes.
Jahagirdar V; Barnett AH
Expert Opin Pharmacother; 2014 Nov; 15(16):2429-41. PubMed ID: 25301180
[TBL] [Abstract][Full Text] [Related]
24. Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials.
DeFronzo RA; Lee C; Kohler S
Adv Ther; 2018 Jul; 35(7):1009-1022. PubMed ID: 29949041
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment.
Macha S; Rose P; Mattheus M; Cinca R; Pinnetti S; Broedl UC; Woerle HJ
Diabetes Obes Metab; 2014 Feb; 16(2):118-23. PubMed ID: 23859534
[TBL] [Abstract][Full Text] [Related]
26. Dapagliflozin: A Review in Type 2 Diabetes.
Dhillon S
Drugs; 2019 Jul; 79(10):1135-1146. PubMed ID: 31236801
[TBL] [Abstract][Full Text] [Related]
27. Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME.
Scheen AJ
Diabetes Res Clin Pract; 2016 Nov; 121():204-214. PubMed ID: 27744129
[TBL] [Abstract][Full Text] [Related]
28. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
Kovacs CS; Seshiah V; Swallow R; Jones R; Rattunde H; Woerle HJ; Broedl UC;
Diabetes Obes Metab; 2014 Feb; 16(2):147-58. PubMed ID: 23906415
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers.
Macha S; Dieterich S; Mattheus M; Seman LJ; Broedl UC; Woerle HJ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):132-40. PubMed ID: 23253948
[TBL] [Abstract][Full Text] [Related]
30. DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1407-1417. PubMed ID: 27435042
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes.
Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):211-223. PubMed ID: 27817207
[TBL] [Abstract][Full Text] [Related]
32. [New fixed combination in type 2 diabetes].
Red
MMW Fortschr Med; 2016 Apr; 158(7):74. PubMed ID: 27071602
[No Abstract] [Full Text] [Related]
33. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
[TBL] [Abstract][Full Text] [Related]
34. Combination therapy for patients with uncontrolled type 2 diabetes mellitus: adding empagliflozin to pioglitazone or pioglitazone plus metformin.
Blevins T
Expert Opin Drug Saf; 2015 May; 14(5):789-93. PubMed ID: 25789798
[TBL] [Abstract][Full Text] [Related]
35. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
Friedrich C; Metzmann K; Rose P; Mattheus M; Pinnetti S; Woerle HJ
Clin Ther; 2013 Jan; 35(1):A33-42. PubMed ID: 23328275
[TBL] [Abstract][Full Text] [Related]
36. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.
Aronson R
Curr Med Res Opin; 2015 May; 31(5):901-11. PubMed ID: 25775379
[TBL] [Abstract][Full Text] [Related]
37. Impact of empagliflozin in patients with diabetes and heart failure.
Pham D; Albuquerque Rocha N; McGuire DK; Neeland IJ
Trends Cardiovasc Med; 2017 Feb; 27(2):144-151. PubMed ID: 27612553
[TBL] [Abstract][Full Text] [Related]
38. Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects.
Kim S; Jang IJ; Shin D; Shin DS; Yoon S; Lim KS; Yu KS; Li J; Zhang H; Liu Y; Brendel E; Blode H; Wang Y
J Clin Pharm Ther; 2014 Aug; 39(4):424-31. PubMed ID: 24806030
[TBL] [Abstract][Full Text] [Related]
39. A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes.
Neeland IJ; Salahuddin U; McGuire DK
Expert Opin Drug Saf; 2016; 15(3):393-402. PubMed ID: 26695551
[TBL] [Abstract][Full Text] [Related]
40. Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.
Scheen AJ
Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1303-1316. PubMed ID: 28984487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
